Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10930475 | Cytotherapy | 2015 | 19 Pages |
Abstract
HAdV-streptamers were shown to be clinically feasible for few patients after the large-scale approach but for larger patient numbers if combined with EBV-streptamers or after the small-scale approach.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Christine Freimüller, Julia Stemberger, Michaela Artwohl, Lothar Germeroth, Volker Witt, Gottfried Fischer, Sabine Tischer, Britta Eiz-Vesper, Ilka Knippertz, Jan Dörrie, Niels Schaft, Thomas Lion, Gerhard Fritsch, René Geyeregger,